Maruani Annabel, Brown Shanna, Lorette Gerard, Pondaven-Letourmy Soizick, Herbreteau Denis, Eisenbaum Allan
Department of Dermatology, CHRU Tours, Inserm U930, University Francois Rabelais Tours, Tours, France.
Pediatr Dermatol. 2013 May-Jun;30(3):383-5. doi: 10.1111/j.1525-1470.2012.01864.x. Epub 2012 Sep 25.
Vascular lesions such as hemangiomas and lymphangiomas can cause significant mortality and morbidity, as well as amblyopia when located in the orbit. Oral propranolol can regress infantile hemangioma during infancy and up to 23 months of age, but its effect on lymphangioma has not been demonstrated. We present two cases of lymphatic malformations treated with oral propranolol. Patient 1 is a 2-year-old boy with macrocystic bilateral cervical lymphangioma extending to the pharynx and larynx and microcystic lymphangioma of the tongue. The patient was started on propranolol 2 mg/kg/day starting at 17 months of age, and after 3 months only a very slight decrease in tongue volume was noted. Patient 2 is a 3.5-year-old boy with magnetic resonance imaging evidence of right facial complex lymphangioma with venous malformation. The patient was placed on oral propranolol 2 mg/kg/day. After 3 months of treatment, no change in the lesion was noted except for a transient decrease in the size of the conjunctival telangiectasia. Propranolol 2 mg/kg/day was not effective in treating lymphatic malformations in two children, both older than 17 months at the time of treatment.
血管瘤和淋巴管瘤等血管性病变可导致严重的死亡率和发病率，若位于眼眶还可引起弱视。口服普萘洛尔可使婴儿期及23个月龄以内的婴儿血管瘤消退，但其对淋巴管瘤的疗效尚未得到证实。我们报告两例接受口服普萘洛尔治疗的淋巴管畸形病例。病例1是一名2岁男孩，患有双侧大囊型颈部淋巴管瘤，延伸至咽和喉，以及舌部微囊型淋巴管瘤。该患者于17个月龄开始服用普萘洛尔，剂量为2mg/kg/天，3个月后仅发现舌体积略有减小。病例2是一名3.5岁男孩，磁共振成像显示右侧面部复合性淋巴管瘤伴静脉畸形。该患者口服普萘洛尔，剂量为2mg/kg/天。治疗3个月后，除结膜毛细血管扩张大小短暂减小外，病变无变化。对于两名治疗时年龄均超过17个月的儿童，2mg/kg/天的普萘洛尔治疗淋巴管畸形无效。
